Members - Dr. Nicholas Zdenkowski

BMED, FRACP, PHD Medical Oncologist/Research Fellow Calvary Mater Newcastle NSW, Australia

Dr Nick Zdenkowski is a Medical Oncologist and Clinical Research Fellow at the Calvary Mater Newcastle, a tertiary referral cancer hospital in NSW, Australia, affiliated with the University of Newcastle. He also consults at The Breast and Endocrine Centre, a breast cancer multidisciplinary clinic within the Hunter Cancer Centre. He holds a Conjoint Lecturer appointment with the University of Newcastle and is a Fellow of the Royal Australasian College of Physicians.

He completed his medical degree at the University of Newcastle before undertaking physician training at Royal North Shore Hospital in Sydney. His Medical Oncology training was at the Calvary Mater Newcastle, during which time he also completed a Clinical Diploma of Palliative Care. He developed expertise in breast cancer clinical trials during a Fellowship with the Australia and New Zealand Breast Cancer Trials Group (ANZBCTG), and completed a Graduate Diploma in Clinical Epidemiology. He is a member of the ANZBCTG Scientific Advisory Committee, the Hunter Cancer Research Alliance Implementation Steering Committee and the PALLAS Study international Steering Committee. He is a principal investigator on several international and national clinical trials including PALLAS, LATER, IBIS 1 & 2, BIG 1-98, and TailorX. He has also led multiple investigator initiated trials in breast, pancreatic and colorectal cancer.

His subspecialty interest is in management of patients with breast cancer, particularly shared decision-making and neoadjuvant systemic therapy. He is now in the final phase of a PhD investigating the role of a decision aid to support shared decision-making for women considering neoadjuvant systemic therapy for operable breast cancer. He would like to see clinical research embedded in routine practice, for greater opportunities for patients and the research community in efficiently generating results that improve the outcomes for patients with cancer.